Target Price | $3.34 |
Price | $0.82 |
Potential |
306.07%
register free of charge
|
Number of Estimates | 4 |
4 Analysts have issued a price target Seres Therapeutics Inc 2025 .
The average Seres Therapeutics Inc target price is $3.34.
This is
306.07%
register free of charge
$10.00
1,116.69%
register free of charge
$1.00
21.67%
register free of charge
|
|
A rating was issued by 8 analysts: 5 Analysts recommend Seres Therapeutics Inc to buy, 1 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Seres Therapeutics Inc stock has an average upside potential 2025 of
306.07%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 126.33 | 31.00 |
1,671.81% | 75.46% | |
EBITDA Margin | -72.96% | -455.10% |
97.77% | 523.77% | |
Net Margin | -106.82% | -383.92% |
97.83% | 259.40% |
5 Analysts have issued a sales forecast Seres Therapeutics Inc 2024 . The average Seres Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Seres Therapeutics Inc EBITDA forecast 2024. The average Seres Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Seres Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Seres Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.89 | -0.78 |
61.47% | 12.36% | |
P/E | negative | |
EV/Sales | 9.07 |
6 Analysts have issued a Seres Therapeutics Inc forecast for earnings per share. The average Seres Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Seres Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Seres Therapeutics Inc...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.